FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Allergan stock soars on deal rumors

Tools

Wall Street is abuzz today with talk that Allergan may be on the block. Options traders have snapped up 13,000 April contracts--yep, that's 13,000, way beyond the normal volume. Apparently, they were set in motion by a web report that GlaxoSmithKline might be interested in the Botox-maker.

At press time, Allergan stock was up around 10 percent to over $47--after leaping by 13 percent earlier in the day, exceeding its 50-day moving average. Drug stocks in general were up, so some of Allergan's rise could be overall market pressure. And it's true that some analysts have tagged Allergan as a buy lately. And Fast Money yesterday recommended an Allergan buy for first thing today.

But professional traders are the options-buyers that swooped in for those thousands of contracts--and that's not a standard-issue up-market move. So what's going on? GSK won't comment, and Allergan won't either.

- see the story at Option Monster
- get more from The Street
- read the brief at MarketWatch

Related Articles:
Bristol, Allergan chiefs nab big raises
Anticipating sales declines, Allergan cuts 460
FDA approves Allergan's eyelash-growth drug
Cosmetic pharma remains steady in downturn


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Mergers and Acquisitions   Pharma Stocks   Allergan  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.